Company Overview and News

 
Credit Suisse-Backed Online Lender to Plan $500 Million IPO - Bloomberg

2017-11-23 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
Billionaire-Backed WeLab Raises $220 Million in Fresh Funding - Bloomberg

2017-11-08 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
Opinion: The jackpot beckons in Hong Kong’s IPOs of ‘One Belt, One Road’ funds

2017-05-11 scmp
Here’s an idea for Hong Kong’s tycoons to take the ‘One Belt, One Road’ off their list: raise a fund based on the concept, similar to the internet-fueled frenzy of Tom.com in 2000.

 
Annual Financial Report 2016

2017-04-28 londonstockexchange
Unit 607, 6th Floor, FWD Financial Centre, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

 
Annual Financial Report 2015

2016-04-29 londonstockexchange
Unit 607, 6th Floor, FWD Financial Centre, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

 
Khazanah buys into China’s WeLab

2016-01-20 thestar.com.my
PETALING JAYA: Sovereign wealth fund Khazanah Nasional Bhd has bought into China’s WeLab, a mobile lending and credit analytics platform player, with an investment of US$160mil (RM701mil) in a fundraising exercise.

 
WeLab raises 1 bn yuan in push to expand micro lending to China’s rural communities

2016-01-20 scmp
Plans are to target individuals aged between 20 to 35 via an internet platform

 
WeLab raises 1 bn yuan in push to bring micro lending to China’s rural youth

2016-01-20 scmp
Plans are to target individuals aged between 20 to 35 internet-enabled devices

 
ING looks worldwide for technology investments, Legrand says

2016-01-20 theedgemarkets
BEIJING (Jan 20): ING Groep NV is looking worldwide for more financial-technology investments as the Dutch firm seeks to build its capabilities in areas from lending and payments to money management. “Geography is not a selection criteria,” Benoit Legrand, ING’s head of fintech, said in an interview from Beijing on Wednesday. “We are working on deals in Europe but we are really open to any deals.”

 
Khazanah, ING invest in online lending platform backed by China billionaire Li

2016-01-20 themalaymailonline
BEIJING, Jan 20 ― ING Groep NV’s banking unit and a Malaysian sovereign wealth fund have bought stakes in WeLab, an operator of online lending platforms backed by Asia’s richest man Li Ka-shing. ING Bank, Malaysia’s Khazanah Nasional Bhd. and

 
Khazanah-led group invests US$160 million in HK start-up WeLab

2016-01-20 themalaysianinsider
An investment group led by Malaysia's state fund Khazanah Nasional has invested US$160 million (RM700 million) in Hong Kong-based financial technology…

 
Khazanah invests US$160m in China's mobile lending platform WeLab

2016-01-20 theedgemarkets
KUALA LUMPUR (Jan 20): Khazanah Nasional Bhd has led a consortium to invest in one of China's largest mobile lending and credit analytics platforms, WeLab, to tap into the country's growing consumer loan market that is currently unmet by traditional banking services. In a statement today, via its special purpose vehicle Bukit Galla Investments Ltd, Khazanah said it has invested in WeLab, in a US$160 million Series B fundraising exercise.

 
Khazanah-led consortium buys stake in China's WeLab

2016-01-20 theedgemarkets
KUALA LUMPUR (Jan 20): Khazanah Nasional Bhd, via its special purpose vehicle Bukit Galla Investments Ltd has invested in WeLab, one of China's largest mobile lending and credit analytics platforms, in a US$160 million Series B fundraising exercise. Khazanah led a consortium of investors, which includes ING Bank and Guangdong Financial Technology Group.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

13h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

13h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...